Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...